This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Venclyxto
  • /
  • A Study of MBG453 in Combination With Azacitidine ...
Clinical trial

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

Read time: 3 mins
Last updated:20th Jan 2020
Identifier: NCT04150029

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in) is to rule out excessive toxicity of MBG453, when administered in combination with azacitidine and venetoclax. The primary purpose of the combined Part 1 and Part 2 (Safety run-in and Expansion Part) is to evaluate efficacy of MBG453, when administered in combination with azacitidine and venetoclax in adult patients with newly diagnosed AML, who are not suitable for treatment with intensive chemotherapy.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 80 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Estimated Study Start Date: January 20, 2020
Estimated Primary Completion Date: January 10, 2022
Estimated Study Completion Date: March 28, 2025

Arm:
- Experimental:
MBG453+Venetoclax +Azacitidine

Category Value
Date last updated at source 2019-11-06
Study type(s) Interventional
Expected enrolment 80
Study start date 2020-01-20
Estimated primary completion date 2022-01-10

View full details